Skip to main content

Table 3 In vitro effect of stimulation with atorvastatin (0.001–10 μM) on PBMC and CD4+

From: Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatment

PBMC
  Atorvastatin (μM)
  Control 0.001 0.1 1 5 10
Resting cell viability (% of PI negative)a 100 ± 2.11 101.41 ± 0.64 96.89 ± 3.63 102.82 ± 1.28 = 101.43 ± 2.19
PHA-induced cell viabilityb 100.00 ± 27.59 106.10 ± 9.81 107.40 ± 14.65 107.50 ± 23.48 50.76 ± 42.44* 33.72 ± 20.61**
PHA-induced cell proliferationb 100.00 ± 26.24 98.61 ± 15.79 96.83 ± 35.19 83.47 ± 25.37 62.26 ± 22.45 33.82 ± 22.84**
PHA-induced IL-4 mRNA expressiona 100.00 ± 38.99 = = 103.90 ± 35.17 98.97 ± 40.82 83.34 ± 37.06
PHA-induced IFN-γ mRNA expressiona 100.00 ± 48.40 = = 102.50 ± 32.99 56.97 ± 32.36 17.03 ± 10.88*
  CD4+
   Atorvastatin (μM)
  PHA (10 μg/ml) 0.001 0.1 1 5 10
Cell viabilitya 100 ± 10.66 98.12 ± 2.92 103.60 ± 7.14 84.88 ± 20.64 53.04 ± 17.73* 34.69 ± 17.28**
Cell proliferationb 100.30 ± 34.75 91.92 ± 13.94 105.10 ± 18.60 109.60 ± 42.90 37.38 ± 4.37* 13.03 ± 10.32**
IL-4 mRNA expressiona 100.00 ± 25.99 = = 133.20 ± 64.78 98.97 ± 33.77 62.11 ± 6.19
IFN-γ mRNA expressiona 100.00 ± 39.62 = = 127.20 ± 35.17 123.70 ± 66.18 54.17 ± 27.68
  1. Cells were cultured for 1 (a) or 5 (b) days as appropriate. Values are expressed as percentage of resting values (presented in table as control) or of values obtained after stimulation with PHA (10 ng/ml) and finally expressed as mean ± SD of at least 4–6 separate experiments; P values were assessed by ANOVA followed by Dunnett comparison
  2. * = P < 0.05; ** = and P < 0.0001 vs respective control